A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.

ABSTRACT:

Objective

Survival in epithelial ovarian cancer (EOC) remains poor. Most patients are diagnosed in late stages. Early diagnosis increases the chance of survival. We used the proximity extension assay from Olink Proteomics to search for new protein biomarkers with the potential to improve the diagnostic performance of CA125 and HE4 in patients with ovarian tumors.

Material and methods

Plasma samples were obtained from 180 women with ovarian tumors; 30 cases of benign tumor, 28 cases with borderline tumors, 25 early EOC cases (FIGO stage I) and 97 advanced EOC cases (FIGO stages II-IV). Proteins were measured using the Olink® Oncology II and Inflammation panels. For statistical analyses, patients were categorized into benign tumors versus cancer and benign tumors versus border

SUBMITTER: Leandersson P 

PROVIDER: S-EPMC7571712 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature